ADMA BIOLOGICS, INC. (ADMA)
ADMA BIOLOGICS, INC. (ADMA) from its SEC filings: 2025 revenue $510.2 million (+20% vs the year before), net margin 29%, free cash flow $27.8 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Revenue (2025) | $510.2 million |
| Revenue growth | +20% |
| Net income | $146.9 million |
| Net margin | 28.8% |
| Free cash flow | $27.8 million |
| Diluted EPS | $0.60 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +2% |
| Cash | $136.0 million |
| Long-term debt | $192.8 million |
| Share count, 1 year | -6% |
| Fundamentals check | Strong fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.